532296 Stock Overview
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Glenmark Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,079.55 |
| 52 Week High | ₹1,095.95 |
| 52 Week Low | ₹520.10 |
| Beta | 0.88 |
| 1 Month Change | 12.95% |
| 3 Month Change | 21.26% |
| 1 Year Change | 95.89% |
| 3 Year Change | 90.63% |
| 5 Year Change | 72.31% |
| Change since IPO | 3,998.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532296 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.5% | -0.1% | 1.8% |
| 1Y | 95.9% | 55.9% | 46.4% |
Return vs Industry: 532296 exceeded the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: 532296 exceeded the Indian Market which returned 46.4% over the past year.
Price Volatility
| 532296 volatility | |
|---|---|
| 532296 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 532296's share price has been volatile over the past 3 months.
Volatility Over Time: 532296's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 15,556 | Glenn Saldanha | www.glenmarkpharma.com |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors.
Glenmark Pharmaceuticals Limited Fundamentals Summary
| 532296 fundamental statistics | |
|---|---|
| Market cap | ₹304.85b |
| Earnings (TTM) | -₹7.64b |
| Revenue (TTM) | ₹131.58b |
2.3x
P/S Ratio-39.9x
P/E RatioIs 532296 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532296 income statement (TTM) | |
|---|---|
| Revenue | ₹131.58b |
| Cost of Revenue | ₹50.39b |
| Gross Profit | ₹81.19b |
| Other Expenses | ₹88.83b |
| Earnings | -₹7.64b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.08 |
| Gross Margin | 61.70% |
| Net Profit Margin | -5.81% |
| Debt/Equity Ratio | 53.2% |
How did 532296 perform over the long term?
See historical performance and comparison